Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: Assessment of methods

Journal of Nuclear Medicine

Volumn 48, Issue 7, 2007, Pages 1207-1215

  Treyer, Valerie ^a   Streffer, Johannes ^b   Wyss, Matthias T ^a   Bettio, Andrea ^c   Ametamey, Simon M ^c   Fischer, Uta ^b   Schmidt, Mark ^d   Gasparini, Fabrizio ^d   Hock, Christoph ^b   Buck, Alfred ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

11C ABP688; Kinetic modeling; mGlu 5; Molecular imaging; Positron emission tomography

Indexed keywords

3 (6 METHYLPYRIDIN 2 YLETHYNYL)CYCLOHEX 2 ENONE O METHYL OXIME C 11; ABP 688; CARBON 11; METABOTROPIC RECEPTOR 5; UNCLASSIFIED DRUG;

ADULT; APPARATUS; ARTICLE; CEREBELLUM; CINGULATE GYRUS; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG SYNTHESIS; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; INTERMETHOD COMPARISON; KINETICS; MALE; MOLECULAR IMAGING; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VOLUNTEER;

ADULT; BRAIN; CARBON RADIOISOTOPES; EVALUATION STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MODELS, BIOLOGICAL; OXIMES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 34447343093     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.039578     Document Type: Article

References (26)

1. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 1995;34:1-26.
2. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol. 2003;14:257-277.
3. Gasparini F, Lingenhohl K, Stoehr N, et al. 2-Methyl-6-(phenylethynyl)- pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 1999;38:1493-1503.
4. Kuhn R, Pagano A, Stoehr N, et al. In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article. Amino Acids. 2002;23:207-211.
5. Spooren W, Gasparini F. mGlu5 receptor antagonists: a novel class of anxiolytics? Drug News Perspect. 2004;17:251-257.
6. Spooren WP, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenyl- ethynyl)pyridine in rodents. J Pharmacol Exp Ther. 2000;295:1267-1275.
7. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, et al. Potential anxiolytic-and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132:1423-1430.
8. 3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett. 2002;12:407-409.
9. 3H]methoxyPyEP. an mGluR5 selective radioligand. Life Sci. 2003;73:371-379.
10. Hamill TG, Krause S, Ryan C, et al. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse. 2005;56:205-216.
11. 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med. 2006;47:698-705.
12. 11C-ABP688. J Nucl Med. 2007;48:247-252.
13. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
14. Alport NM, Eriksson L, Chang JY, et al. Strategy for the measurement of regional cerehral blood flow using short-lived tracers and emission tomography. J Cereb Blood Flow Metab. 1984;4:28-34.
15. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab. 1991;11:735-744.
16. Mintun MA, Raichle ME, Kilhourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15:217-227.
17. Buck A, Westera G, vonSchulthess GK, Burger C. Modeling alternatives for cerebral carbon-11-iomazenil kinetics. J Nucl Med. 1996;37:699-705.
18. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;AC19:716-723.
19. 18F] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24-42.
20. 11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab. 1999; 19:1150-1163.
21. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661-670.
22. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096-1112.
23. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
24. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22:1440-1452.
25. 11C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a beta-scintillator. Neuroimage. 2007;35:1086-1092.
26. 18F-FDG PET measures in differentiating dementias. J Nucl Med. 2005;46:936-944.